Factor XII plays a pathogenic role in organ failure and death in baboons challenged with Staphylococcus aureus.
Animals
Antibodies
/ therapeutic use
Blood Coagulation Disorders
/ complications
Blood Platelets
/ metabolism
Cellular Microenvironment
Complement Activation
Factor XII
/ immunology
Female
Fibrinogen
/ metabolism
Hot Temperature
Inflammation
/ complications
Male
Multiple Organ Failure
/ immunology
Papio
Staphylococcal Infections
/ drug therapy
Staphylococcus aureus
/ physiology
Survival Analysis
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
02
10
2020
accepted:
26
01
2021
pubmed:
19
2
2021
medline:
31
7
2021
entrez:
18
2
2021
Statut:
ppublish
Résumé
Activation of coagulation factor (F) XI promotes multiorgan failure in rodent models of sepsis and in a baboon model of lethal systemic inflammation induced by infusion of heat-inactivated Staphylococcus aureus. Here we used the anticoagulant FXII-neutralizing antibody 5C12 to verify the mechanistic role of FXII in this baboon model. Compared with untreated control animals, repeated 5C12 administration before and at 8 and 24 hours after bacterial challenge prevented the dramatic increase in circulating complexes of contact system enzymes FXIIa, FXIa, and kallikrein with antithrombin or C1 inhibitor, and prevented cleavage and consumption of high-molecular-weight kininogen. Activation of several coagulation factors and fibrinolytic enzymes was also prevented. D-dimer levels exhibited a profound increase in the untreated animals but not in the treated animals. The antibody also blocked the increase in plasma biomarkers of inflammation and cell damage, including tumor necrosis factor, interleukin (IL)-1β, IL-6, IL-8, IL-10, granulocyte-macrophage colony-stimulating factor, nucleosomes, and myeloperoxidase. Based on clinical presentation and circulating biomarkers, inhibition of FXII prevented fever, terminal hypotension, respiratory distress, and multiorgan failure. All animals receiving 5C12 had milder and transient clinical symptoms and were asymptomatic at day 7, whereas untreated control animals suffered irreversible multiorgan failure and had to be euthanized within 2 days after the bacterial challenge. This study confirms and extends our previous finding that at least 2 enzymes of the contact activation complex, FXIa and FXIIa, play critical roles in the development of an acute and terminal inflammatory response in baboons challenged with heat-inactivated S aureus.
Identifiants
pubmed: 33598692
pii: S0006-4971(21)00358-X
doi: 10.1182/blood.2020009345
pmc: PMC8288658
doi:
Substances chimiques
Antibodies
0
Factor XII
9001-30-3
Fibrinogen
9001-32-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
178-189Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM121601
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI062629
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM114731
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL151367
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140025
Pays : United States
Organisme : NIH HHS
ID : P40 OD024628
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 by The American Society of Hematology.
Références
J Clin Invest. 1993 Jan;91(1):61-8
pubmed: 7678610
Blood. 1996 Mar 15;87(6):2337-44
pubmed: 8630396
Blood. 2018 Aug 23;132(8):849-860
pubmed: 29921614
J Innate Immun. 2018;10(2):94-105
pubmed: 29237166
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2118-2127
pubmed: 28743596
Sci Transl Med. 2014 Feb 5;6(222):222ra17
pubmed: 24500405
Thromb Res. 2010 Mar;125(3):210-5
pubmed: 20022081
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Alzheimers Dement (Amst). 2018 Aug 04;10:480-489
pubmed: 30310850
Shock. 2015 Sep;44(3):265-71
pubmed: 25944792
Infect Immun. 2012 Jan;80(1):91-9
pubmed: 22006565
Blood. 2014 Mar 13;123(11):1739-46
pubmed: 24408325
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1748-1760
pubmed: 30354195
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):674-680
pubmed: 29222320
Res Pract Thromb Haemost. 2020 Feb 11;4(2):205-216
pubmed: 32110750
J Thromb Haemost. 2018 Mar;16(3):441-454
pubmed: 29251820
J Crit Care Med (Targu Mures). 2017 May 11;3(2):63-69
pubmed: 29967873
Blood Adv. 2019 Feb 26;3(4):658-669
pubmed: 30808684
J Infect Dis. 2008 Jul 15;198(2):271-4
pubmed: 18491973
J Clin Med. 2019 May 22;8(5):
pubmed: 31121897
Semin Thromb Hemost. 2018 Feb;44(1):60-69
pubmed: 28898903
Blood. 2012 May 17;119(20):4762-8
pubmed: 22442348
Am J Pathol. 1992 Apr;140(4):897-906
pubmed: 1373271
Med Clin North Am. 2020 Jul;104(4):573-585
pubmed: 32505253
Arterioscler Thromb Vasc Biol. 1995 May;15(5):612-21
pubmed: 7749875
Res Pract Thromb Haemost. 2019 May 23;3(3):331-339
pubmed: 31294319
Front Immunol. 2019 Aug 22;10:2011
pubmed: 31507606
Am J Hum Genet. 2006 Dec;79(6):1098-104
pubmed: 17186468
PLoS One. 2016 Apr 05;11(4):e0152968
pubmed: 27046148
J Clin Invest. 2018 Mar 1;128(3):944-959
pubmed: 29376892
Shock. 2000 Feb;13(2):100-9
pubmed: 10670839
N Engl J Med. 2012 May 31;366(22):2055-64
pubmed: 22616830
Arterioscler Thromb Vasc Biol. 1997 Aug;17(8):1550-60
pubmed: 9301635
Thromb Haemost. 1991 Feb 12;65(2):117-21
pubmed: 1905067
Res Pract Thromb Haemost. 2019 Jun 19;3(4):599-606
pubmed: 31624779
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6390-E6399
pubmed: 28720697